Effect of Hybrid Closed-Loop Insulin Delivery System on Glycemic Management in Perioperative Patients With Type 2 Diabetes Receiving Parenteral Nutrition: An Open-Label, Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Glycemic control in surgical patients with type 2 diabetes mellitus (T2DM) receiving parenteral nutrition represents a major clinical challenge. This randomized controlled trial evaluates the comparative effectiveness and safety of hybrid closed-loop (HCL) insulin delivery versus conventional insulin pumps combined with continuous glucose monitoring (CGM) in perioperative T2DM patients requiring short-term parenteral nutrition.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years.

• Diagnosis of T2DM requiring surgical procedures (duration ≥2 hours) with anticipated short-term total parenteral nutrition (TPN) during the perioperative period (expected hospitalization \>72 hours).

• Glycemic control criteria (meeting any of the following):

• ①HbA1c ≥7.5% or random plasma glucose ≥13.9 mmol/L

⁃ Established T2DM with poor glycemic control (HbA1c ≥7.5%) despite combination therapy (≥2 oral antidiabetic drugs) ③Insulin-treated patients with suboptimal control (HbA1c ≥7.0%) after adequate dose adjustment.

• Willing to sign the informed consent form.

Locations
Other Locations
China
Department of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University, Changsha, Hunan 410011
RECRUITING
Changsha
Contact Information
Primary
Xia Li, MD, PhD
lixia2014@vip.163.com
+86 13974885753
Time Frame
Start Date: 2025-06-26
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 40
Treatments
Experimental: Hybrid closed-loop insulin delivery system
T2DM patients in the experimental group will receive the hybrid closed-loop insulin delivery system.
Active_comparator: Conventional insulin pump with CGM
T2DM patients in the control group will receive conventional insulin pump therapy with CGM.
Related Therapeutic Areas
Sponsors
Leads: Second Xiangya Hospital of Central South University

This content was sourced from clinicaltrials.gov